30 October - 2 November 2019

50th Union World Conference on Lung Health

The newest Global TB Report stresses that tuberculosis cannot be stopped without new tools, drugs and ways of working. Unitaid has been intensifying its TB investments to bring about these crucial innovations.

At this week’s Union Conference, Unitaid presents new projects that are developing child-friendly treatments and preventive therapy for multidrug-resistant tuberculosis, bringing in fast, accurate, gene-based diagnosis, and piloting technologies to help patients adhere to TB treatment. We are honored to play a role in #EndingTheEmergency.

We are also excited to announce a landmark agreement between Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria and global biopharmaceutical company Sanofi that will significantly lower the price – by nearly 70% — of rifapentine, a critically important drug used to prevent TB. The deal could stop millions from developing the life-threatening disease.


Our press releases:


Unitaid in the Press:


Unitaid’s work in TB:


Watch our short films and animations:


For more information on the 50th Union World Conference on Lung Health, please visit its official website: https://hyderabad.worldlunghealth.org

Share on Twitter

News and Press Releases

Oct 31, 2019

Landmark deal secures significant discount on price of medicine to prevent TB

Read More

Nov 01, 2019

Unitaid introduces its newest tuberculosis-fighting projects at Union World Conference

Read More


Fighting MDR-TB in Peru

Peru has the highest burden of multidrug-resistant tuberculosis (MDR-TB) in Latin America. Patients with MDR-TB currently have to endure a painful two-year treatment involving as many as 20 pills a day and injectables, which can cause psychosis and hearing loss. Thanks to a new generation MDR-TB treatment regimen that is simpler, shorter and less toxic, patients are able to get cured more quickly. Unitaid is investing US$80 million to expand access to this treatment.

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.